The purpose of this study was to evaluate the pharmacokinetics of intranasal hydromorphone hydrochloride (HCl) in patients with vasomotor rhinitis. Methods: Ten patients completed the randomised ...

Bioequivalence between 200mg tablets of ibuprofen lysinate and a new 200mg soft gelatin capsule was demonstrated. In accordance with previous results, this study confirmed again the ...

Thursday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) said it has completed a pharmacokinetics (PK) study of AD04 for Alcohol Use ...

The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with ...

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on OLMA stock, giving a Buy rating on November 26.Don't Miss our Black ...

R289, a dual IRAK1/4 inhibitor, has received fast track status from the FDA for treating transfusion-dependent lower-risk MDS ...

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...

Rigel Pharmaceuticals (RIGL) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to R289 for the ...

Ray Lambert looks at the potential of humanized FcRn mice for evaluating the pharmacokinetics of mAbs. Due to their extraordinary specificity and pharmacokinetic (PK) behavior, human ...

Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no ...

The company plans to engage with the FDA during the fourth quarter of 2024 with the results of this pharmacokinetics study and obtain feedback that will assist with the AD04 Phase 3 study program.